New anti-CD269 (BCMA) antibody available!
New anti-CD269 (BCMA) antibody available! Purified (with antibiotic) catalog # 269-020 Purified (preservative-free) catalog # 269-020
New anti-CD269 (BCMA) antibody available! Read More »
New anti-CD269 (BCMA) antibody available! Purified (with antibiotic) catalog # 269-020 Purified (preservative-free) catalog # 269-020
New anti-CD269 (BCMA) antibody available! Read More »
Ancell is proud to be a sponsor of the 2012 Autumn Immunology Conference in Chicago Nov 16th -Nov 19th. Visit us at booth #18!
Ancell at AIC in Chicago Read More »
“Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients” Kwek S S, L Fong, et al. (Oct 2012) J Immunol 189(7): 3759-3766. “…advanced prostate cancer patients who clinically respond to treatment also develop enhanced Ab responses to a higher number of Ags than nonresponders…” Relevant Ancell Products Anti-CD152(CTLA-4) blocking mAb
”CD49d provides access to “untouched” human Foxp3 Treg free of contaminating effector cells” Kleinewietfeld M, K Falk, et al. (2012) Blood 113(4): 827-836. Magnetic depletion of PBMC using anti-CD127 (Clone hIL7R-M21) and anti-CD49d (Clone BU49) mAbs to yield a pure population of Foxp3 + Treg cells! Relevant Ancell products: anti-CD49d (clone BU49) anti-CD127
CD49d is a useful marker for sorting FoxP3+ human Treg Read More »
“B7-DC-Ig Enhances Vaccine Effect by a Novel Mechanism Dependent on PD-1 Expression level on T Cell Subsets” M. Mkrtichyan, S.N. Khleif, et al. (2012) J Immunol 189(5): 2338-2347. Engagement of CD279(PD-1) by recombinant CD273 (B7-DC)-muIg enhances effect of anti-tumor vaccine in mice. Two proposed mechanisms by which this recombinant protein may augment anti tumor
PD-1 engagement enhances anti-tumor vaccine in mice Read More »
Cutting Edge: IL-2 Signals Determine the Degree of TCR Signaling Necessary To Support Regulatory T Cell Proliferation In Vivo. Zou T, Kambayashi T. et al. J Immunol. 2012 Jul 1;189(1):28-32. It has been thought that proliferation of T regulatory cells in vivo was dependent on signaling from T cell receptor –MHC Class II interaction. Zou
In vivo Treg proliferation from IL-2 signaling alone Read More »
“Human Th17 Cells Express High Levels of Enzymatically active Dipeptidylpeptidase IV (CD26)” Bengsch B, R Thimme, et al, (2012) J Immunol 188(11): 5438-5447. In transwell assays, CD26(bright) Th17 cells inhibited chemotaxis of CXCR4+ Th1 T cells towards CXCL12. CD26 appears to be an interesting and useful marker for Th17 autoimmunity. Ancell anti-CD26 reagents (clone 202.36):
CD4+ CD26(bright) Human T cells display Th17 phenotype Read More »
A link found between autoimmune antibody specificity to Citrullinated Protein and development of Rheumatoid Arthritis. “Production of Autoantibodies against Citrullinated Antigens/Peptides by Human B Cells” Maria F. Bellatin, Peter Stastny, et al. (2012) J Immunol 188(7): 3542-3550 Ancell has a large selection of Biotinylated anti-human monoclonal antibodies which would be useful for sorting and/or identifying
Citrullinated Protein and RA Read More »
Levels of the proinflammatory leptin correlated inversely with expansion of CD25+CD4+Foxp3+ T regulatory cells in a Systemic Lupus Erythematosus mouse model (NZB/W). This could lead to a leptin-based immunotherapy.”Cutting Edge: Fasting Induced Hypoleptinemia Expands Functional Regulatory T cells in Systemic Lupus Erythematosus”Yaoyang Liu, Yiyun Yu, Antonio La Cava, (2012) J Immunol 188: 2070-2073. Relevant Ancell
Leptin affects Treg populations in SLE Read More »
Increased Expression of CD229(SLAMF3) and CD352(SLAMF6) in SLE T Lymphocytes Promotes Th17 Differentiation Chatterjee M., G.C. Tsokos, et al. (2012) J Immunol 188: 1206-1212.
SLAM receptors infulence TH17 Differentialtion in SLE Read More »